Fitness study for children and young adults with ITP
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This study looks at how fit children, teens, and young adults with ITP (immune thrombocytopenic purpura) are. It involves a fitness test to help doctors understand exercise ability in people with this condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 8 and 25 years old.
- You have been diagnosed with chronic immune thrombocytopenic purpura (ITP).
- You are being referred by an expert doctor in the CEREVANCE network for a fitness check-up.
- You do not have any medical condition that would make exercise unsafe (like severe anemia, uncontrolled asthma, or heart problems).
- You are able to follow instructions and cooperate during the test.
- You have health insurance (social security) coverage.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an IV medicine called efgartigimod for teenagers (ages 12 to under 18) who have had chronic immune thrombocytopenia (ITP) for more than a year. The goal is to see if it can safely help raise platelet counts.
This trial studies whether a “dose-dense” rituximab schedule can help children and teens with newly diagnosed, high-risk immune thrombocytopenia (ITP). It aims to raise/maintain platelet counts and control bleeding, while carefully checking safety.
This trial studies a short, high-dose steroid plan (prednisone plus dexamethasone) to treat immune thrombocytopenia (ITP) in children and raise low platelet counts. It may help reduce bleeding risk while using an approach tested in children soon after diagnosis.
This trial compares two treatments for adults recently diagnosed with immune thrombocytopenia (ITP) whose platelet count is very low and hasn't improved with standard steroids. The goal is to find a better way to raise platelet counts and reduce bleeding risk.
This trial tests an IV medicine called V-IMMUNE® for people with immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding. The study aims to see if V-IMMUNE® can safely raise platelet counts in both children and adults.
This trial studies whether “TPO” medicines (like eltrombopag or similar drugs) help people age 14 and older with primary immune thrombocytopenia (ITP) who did not respond well to first treatments. It may help raise platelet counts and reduce bleeding, especially when prior therapy hasn’t worked.
Hear when a new Immune Thrombocytopenic Purpura trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.